Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+metastatic breast cancer with and without brain metastases (HER2CLIMB).

This article has no abstract
Epistemonikos ID: 820f1025b479e3585f88d031f36efb470c291c60
First added on: Feb 13, 2025